About: Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future
Creator	Ghosh, Souvik Kobayashi, Nobumichi Singh, Yashpal
source	PMC
abstract	BACKGROUND: Noroviruses and rotaviruses are important viral etiologies of severe gastroenteritis. Noroviruses are the primary cause of nonbacterial diarrheal outbreaks in humans, whilst rotaviruses are a major cause of childhood diarrhea. Although both enteric pathogens substantially impact human health and economies, there are no approved drugs against noroviruses and rotaviruses so far. On the other hand, whilst the currently licensed rotavirus vaccines have been successfully implemented in over 100 countries, the most advanced norovirus vaccine has recently completed phase-I and II trials. METHODS: We performed a structured search of bibliographic databases for peer-reviewed research litera-ture on advances in the fields of norovirus and rotavirus therapeutics and immunoprophylaxis. RESULTS: Technological advances coupled with a proper understanding of viral morphology and replication over the past decade has facilitated pioneering research on therapeutics and immunoprophylaxis against noroviruses and rotaviruses, with promising outcomes in human clinical trials of some of the drugs and vaccines. This review focuses on the various developments in the fields of norovirus and rotavirus thera-peutics and immunoprophylaxis, such as potential antiviral drug molecules, passive immunotherapies (oral human immunoglobulins, egg yolk and bovine colostral antibodies, llama-derived nanobodies, and anti-bodies expressed in probiotics, plants, rice grains and insect larvae), immune system modulators, probiot-ics, phytochemicals and other biological substances such as bovine milk proteins, therapeutic nanoparti-cles, hydrogels and viscogens, conventional viral vaccines (live and inactivated whole virus vaccines), and genetically engineered viral vaccines (reassortant viral particles, virus-like particles (VLPs) and other sub-unit recombinant vaccines including multi-valent viral vaccines, edible plant vaccines, and encapsulated viral particles). CONCLUSIONS: This review provides important insights into the various approaches to therapeutics and im-munoprophylaxis against noroviruses and rotaviruses..
has issue date	2018-03-01(xsd:dateTime)
bibo:doi	10.2174/1389200218666170912161449
bibo:pmid	28901254
has license	cc-by-nc
sha1sum (hex)	bd71b1a62a406002b599f93967b26d84f1d3f8fc
schema:url	https://doi.org/10.2174/1389200218666170912161449
resource representing a document's title	Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future
has PubMed Central identifier	PMC5971199
has PubMed identifier	28901254
schema:publication	Curr Drug Metab
resource representing a document's body	covid:bd71b1a62a406002b599f93967b26d84f1d3f8fc#body_text
is schema:about of	named entity 'ENTERIC' named entity 'ROTAVIRUSES' named entity 'ROTAVIRUS VACCINES' named entity 'OUTBREAKS' named entity 'DRUGS' named entity 'BACKGROUND' named entity 'SEVERE' named entity 'rotavirus vaccines' named entity 'norovirus' named entity 'phase-I' named entity 'Noroviruses' named entity 'human health' named entity 'gastroenteritis' named entity 'diarrhea' named entity 'international journal' named entity 'international journal' named entity 'Current Drug Metabolism' named entity 'catalytic triad' named entity 'vesicular stomatitis virus' named entity 'foscarnet' named entity 'Glycyrrhiza glabra' named entity 'rotavirus gastroenteritis' named entity 'pentavalent vaccine' named entity 'murine norovirus' named entity 'PLGA' named entity 'low birthweight' named entity 'antiviral drug' named entity 'INFs' named entity 'phase-III' named entity 'VLPs' named entity 'probiotics' named entity 'virus' named entity 'vaccine' named entity 'Liévin' named entity 'GTP' named entity 'immunocompromised patients' named entity 'Favipiravir' named entity 'protein' named entity 'viral particles' named entity 'VP7' named entity 'virus replication' named entity 'host cell' named entity 'PDI' named entity 'kDa' named entity 'norovirus' named entity 'subunit vaccine' named entity 'Neomycin' named entity 'virus' named entity 'VP6' named entity 'higher concentration' named entity 'intracellular' named entity 'protein' named entity 'Suramin' named entity 'vaccine strain' named entity 'viral RNA' named entity 'vaccine' named entity 'intussusception' named entity 'Bismuth Subsalicylate' named entity 'Mass spectrometry' named entity 'cytidine' named entity 'mRNA' named entity 'norovirus' named entity 'oxido-reductase' named entity 'tetravalent' named entity 'NSP1' named entity 'isoprinosine' named entity 'phase-III' named entity 'Actinomycin' named entity 'norovirus' named entity 'egg yolk' named entity 'genome sequencing' named entity 'Rotarix' named entity 'RdRp' named entity 'monoclonal antibodies' named entity 'host cells' named entity 'virus' named entity 'adjuvant' named entity 'rotavirus' named entity 'green tea'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software